Atara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapies
Atara Biotherapeutics Inc (NASDAQ:ATRA) will reduce cash burn by laying off 20% of its staff and extend the cash…
Heron Shares Jump After Equity Financing, Q2 Earnings
Heron Therapeutics Inc (NASDAQ:HRTX) reported Q2 sales of $27.63 million, +23.1% Y/Y, beating the consensus of $24.31 million. Oncology sales…
Endo Shares Plunge On Imminent Bankruptcy Filing
Endo International plc’s (NASDAQ:ENDP) Q2 sales decreased 20% to $569.11 million, beating the consensus of $529.94 million. The decrease was…
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) non-opioid painkiller. The company…
Merck Re-enters Alzheimer’s R&D With Research Pact With Cerevance
Cerevance, a private, clinical-stage drug discovery and development company, announced a multi-year strategic research collaboration with Merck & Co Inc (NYSE:MRK). The…
NeuroOne Seeks Again FDA Clearance For sEEG Electrode In Brain Mapping Diagnostics
NeuroOne Medical Technologies (NASDAQ: NMTC) has submitted a special 510(k) to the U.S. Food and Drug Administration (FDA) for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.
FDA Pushes Decision Date For Reata’s Genetic Neuromuscular Disease Candidate
The FDA has extended the review timeline for Reata Pharmaceuticals Inc’s (NASDAQ:RETA) marketing application seeking approval for omaveloxolone for Friedreich’s ataxia by…
Eagle Pharma Broadens Acute Care Portfolio With Equity Stake In Respiratory Depression Player
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has agreed to make a $25 million equity investment in Enalare Therapeutics Inc. The investment consists of upfront…
AstraZeneca’s Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab…
Veru Highlights Presentation Of Phase 3 Study Of Sabizabulin At 11th International Conference on Emerging Infectious Diseases (ICEID) On August 7-10
Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced